JP6193806B2 - 腫瘍壊死因子受容体関連因子7を全身性エリテマトーデスのバイオマーカーとする用途、全身性エリテマトーデスを患う人を検出する方法およびキット - Google Patents
腫瘍壊死因子受容体関連因子7を全身性エリテマトーデスのバイオマーカーとする用途、全身性エリテマトーデスを患う人を検出する方法およびキット Download PDFInfo
- Publication number
- JP6193806B2 JP6193806B2 JP2014105017A JP2014105017A JP6193806B2 JP 6193806 B2 JP6193806 B2 JP 6193806B2 JP 2014105017 A JP2014105017 A JP 2014105017A JP 2014105017 A JP2014105017 A JP 2014105017A JP 6193806 B2 JP6193806 B2 JP 6193806B2
- Authority
- JP
- Japan
- Prior art keywords
- sle
- traf7
- patient
- detecting
- lupus erythematosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 96
- 238000000034 method Methods 0.000 title claims description 44
- 239000000090 biomarker Substances 0.000 title claims description 23
- 108010023321 Factor VII Proteins 0.000 title claims description 5
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title claims description 5
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 238000002965 ELISA Methods 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000003547 immunosorbent Substances 0.000 claims 1
- 238000002731 protein assay Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 230000008816 organ damage Effects 0.000 description 5
- 206010062237 Renal impairment Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002331 protein detection Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Description
本発明は、人がSLEを患っているかどうかを確定するために、SLEを患う人を検出する方法を提供する。
Claims (5)
- 腫瘍壊死因子受容体関連因子7(TRAF7)を全身性エリテマトーデス(SLE)の検出のためのバイオマーカーとして使用する方法。
- SLEの疑いのある患者の血漿試料中の総タンパク質に対するTRAF7の比率と正常な人の血漿試料中の総タンパク質に対するTRAF7の比率を比較するステップ
を含む、請求項1に記載の腫瘍壊死因子受容体関連因子7(TRAF7)を全身性エリテマトーデス(SLE)の検出のためのバイオマーカーとして使用する方法。 - 前記患者の前記血漿試料中の総タンパク質に対するTRAF7の前記比率が、前記正常な人の前記血漿試料中の1.3〜1.5倍である、請求項2に記載の方法。
- タンパク質定量法を用いてTRAF7の濃度を測定することをさらに含む、請求項2に記載の方法。
- 前記タンパク質定量法が、酵素結合免疫吸着法(ELISA)を含む、請求項4に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW102118255A TWI502199B (zh) | 2013-05-23 | 2013-05-23 | 腫瘤壞死因子受體相關因子7作爲紅斑性狼瘡的生物標記物之用途、偵測人體患有紅斑性狼瘡的方法以及偵測人體患有紅斑性狼瘡的套組 |
TW102118255 | 2013-05-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014228547A JP2014228547A (ja) | 2014-12-08 |
JP2014228547A5 JP2014228547A5 (ja) | 2015-09-17 |
JP6193806B2 true JP6193806B2 (ja) | 2017-09-06 |
Family
ID=51935612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014105017A Expired - Fee Related JP6193806B2 (ja) | 2013-05-23 | 2014-05-21 | 腫瘍壊死因子受容体関連因子7を全身性エリテマトーデスのバイオマーカーとする用途、全身性エリテマトーデスを患う人を検出する方法およびキット |
Country Status (3)
Country | Link |
---|---|
US (1) | US20140349316A1 (ja) |
JP (1) | JP6193806B2 (ja) |
TW (1) | TWI502199B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017050976A1 (en) * | 2015-09-23 | 2017-03-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ephb2 polypeptides and uses thereof for the diagnosis and treatment of lupus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055859A2 (en) * | 1998-04-29 | 1999-11-04 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Cd40-interacting and traf-interacting proteins |
JP2003512857A (ja) * | 1999-11-05 | 2003-04-08 | ザ バーナム インスティチュート | Trafファミリータンパク質 |
PT1889065E (pt) * | 2005-05-18 | 2013-09-27 | Novartis Ag | Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória |
-
2013
- 2013-05-23 TW TW102118255A patent/TWI502199B/zh not_active IP Right Cessation
- 2013-11-26 US US14/091,325 patent/US20140349316A1/en not_active Abandoned
-
2014
- 2014-05-21 JP JP2014105017A patent/JP6193806B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW201445140A (zh) | 2014-12-01 |
TWI502199B (zh) | 2015-10-01 |
JP2014228547A (ja) | 2014-12-08 |
US20140349316A1 (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qin et al. | Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients | |
Ueland et al. | Inflammatory cytokines as biomarkers in heart failure | |
Hu et al. | Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus | |
JP5571657B2 (ja) | 生着不全および死に関するマーカー | |
CA2898111C (en) | A method for determining acute respiratory distress syndrome (ards) related biomarkers, a method to monitor the development and treatment of ards in a patient | |
Consolaro et al. | Advances in biomarkers for paediatric rheumatic diseases | |
Oliveira et al. | The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus | |
Vincent et al. | Effect of storage duration on cytokine stability in human serum and plasma | |
US20210116452A1 (en) | Lung cancer biomarkers | |
Liu et al. | Methodological evaluation and comparison of five urinary albumin measurements | |
Khan et al. | Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients with acute myocardial infarction | |
Zhang et al. | Analytical and biological validation of a multiplex immunoassay for acute kidney injury biomarkers | |
US20210373033A1 (en) | Glomerulonephritis biomarkers | |
Zeng et al. | Circulating lncRNA ITSN1‐2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients | |
Gruden et al. | NH2-terminal probrain natriuretic peptide is associated with diabetes complications in the EURODIAB Prospective Complications Study: the role of tumor necrosis factor-α | |
Mirian et al. | Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis | |
Liu et al. | Soluble glycoprotein 130 and heat shock protein 27 as novel candidate biomarkers of chronic heart failure with preserved ejection fraction | |
US20220283157A1 (en) | Multiplexed assay kits for evaluation of systemic lupus erythematosus | |
Hartman et al. | Proenkephalin as a new biomarker for pediatric acute kidney injury–reference values and performance in children under one year of age | |
Gong et al. | Increased serum IL-41 is associated with disease activity in rheumatoid arthritis | |
JP6193806B2 (ja) | 腫瘍壊死因子受容体関連因子7を全身性エリテマトーデスのバイオマーカーとする用途、全身性エリテマトーデスを患う人を検出する方法およびキット | |
Berezhnoy et al. | Maintained imbalance of triglycerides, apolipoproteins, energy metabolites and cytokines in long-term COVID-19 syndrome patients | |
WO2021232211A1 (zh) | 诊断肾病的标志物以及诊断方法 | |
Mitchell et al. | Pro‐Inflammatory Proteins Associated with Frailty and Its Progression—A Longitudinal Study in Community‐Dwelling Women | |
JP2014228547A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170628 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170714 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170810 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6193806 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |